FDA approves Pfizer's Tukysa as front-line maintenance for HER2+ breast cancer
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration has approved Tukysa (tucatinib) in combination with trastuzumab ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




